Form 4 holding
10%+ Owner
Mirati Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 7,396,979
- Estimated value
- $436,569,701
- Report date
- 18 Dec 2023
- Price
- $59.02
- Ownership
- Indirect
EcoR1 Capital, LLC
Insider Reports History
- Reporting-owner location
- San Francisco, CA
- Latest reporting-owner signature
-
/s/ Oleg Nodelman, Manager of EcoR1 Capital, LLC
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for EcoR1 Capital, LLC
Form 4 holding
Director, 10%+ Owner
Zymeworks Inc.
- Security class
- Common Stock
- Shares / value
- 22,970,388
- Estimated value
- $291,953,631
- Report date
- 26 Jun 2025
- Price
- $12.71
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
ANAPTYSBIO, INC
- Security class
- Common Stock
- Shares / value
- 7,880,094
- Estimated value
- $102,051,945
- Report date
- 02 Jan 2025
- Price
- $12.95
- Ownership
- Indirect
Form 4 holding
10%+ Owner
iTeos Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 10,688,978
- Estimated value
- $85,511,824
- Report date
- 15 May 2025
- Price
- $8.00
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Zymeworks Inc.
- Security class
- Pre-Funded Warrants
- Shares / value
- 5,086,521
- Estimated value
- $49,999,993
- Report date
- 26 Dec 2023
- Price
- $9.83
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
PROTHENA CORP PUBLIC LTD CO
- Security class
- Ordinary Shares
- Shares / value
- 5,304,596
- Estimated value
- $40,544,618
- Report date
- 06 May 2025
- Price
- $7.64
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Graphite Bio, Inc.
- Security class
- Common Stock
- Shares / value
- 8,538,446
- Estimated value
- $34,836,860
- Report date
- 06 Jan 2023
- Price
- $4.08
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Tango Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 10,630,736
- Estimated value
- $31,010,920
- Report date
- 07 Nov 2024
- Price
- $2.92
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Voyager Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 3,851,507
- Estimated value
- $27,538,275
- Report date
- 11 Jan 2023
- Price
- $7.15
- Ownership
- Indirect
Form 4 holding
10%+ Owner
TScan Therapeutics, Inc.
- Security class
- Voting Common Stock
- Shares / value
- 5,000,000
- Estimated value
- $24,842,500
- Report date
- 26 May 2023
- Price
- $4.97
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Mersana Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 11,328,000
- Estimated value
- $21,523,200
- Report date
- 19 Dec 2024
- Price
- $1.90
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Atara Biotherapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 1,552,000
- Estimated value
- $14,511,200
- Report date
- 07 May 2026
- Price
- $9.35
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Adaptimmune Therapeutics PLC
- Security class
- Ordinary Shares
- Shares / value
- 100,371,882
- Estimated value
- $10,247,969
- Report date
- 30 Jul 2025
- Price
- $0.1021
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Corvus Pharmaceuticals, Inc.
- Security class
- Common Stock
- Shares / value
- 81,077
- Estimated value
- $64,051
- Report date
- 01 Oct 2021
- Price
- $0.7900
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Mersana Therapeutics, Inc.
- Security class
- Pre-Funded Warrants
- Shares / value
- 8,036,688
- Estimated value
- Report date
- 19 Dec 2024
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
First Tracks Biotherapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 3,174,519
- Estimated value
- Report date
- 20 Apr 2026
- Price
- Ownership
- Indirect
Form 4 holding
Director
Aktis Oncology, Inc.
- Security class
- Common Stock
- Shares / value
- 347,305
- Estimated value
- Report date
- 12 Jan 2026
- Price
- Ownership
- Indirect
Form 4 holding
Director
Aktis Oncology, Inc.
- Security class
- Class A Common Stock
- Shares / value
- 86,222
- Estimated value
- Report date
- 12 Jan 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Aktis Oncology, Inc.
- Security class
- Series A Redeemable Convertible Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 12 Jan 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Aktis Oncology, Inc.
- Security class
- Series B Redeemable Convertible Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 12 Jan 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Odonate Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- Report date
- 10 Dec 2021
- Price
- $1.57
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Zymeworks Inc.
- Security class
- Pre-Funded Warrants (right to acquire)
- Shares / value
- 0
- Estimated value
- Report date
- 26 Jun 2025
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by EcoR1 Capital, LLC
4
ATRA
Atara Biotherapeutics, Inc.
- Report period
- 07 May 2026
- Transactions
- 1
- Transaction value
- +$4,744,255
- Accepted by SEC
- 11 May 2026, 17:34
- Role
- 10%+ Owner
- Next action
- Open filing details
3
ATRA
Atara Biotherapeutics, Inc.
- Report period
- 07 May 2026
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 11 May 2026, 17:33
- Role
- 10%+ Owner
- Next action
- Open filing details
4
TRAX
First Tracks Biotherapeutics, Inc.
- Report period
- 20 Apr 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 22 Apr 2026, 17:07
- Role
- 10%+ Owner
- Next action
- Open filing details
3
TRAX
First Tracks Biotherapeutics, Inc.
- Report period
- 20 Apr 2026
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 22 Apr 2026, 17:07
- Role
- 10%+ Owner
- Next action
- Open filing details
4
AKTS
Aktis Oncology, Inc.
- Report period
- 12 Jan 2026
- Transactions
- 12
- Transaction value
- +$39,999,996
- Accepted by SEC
- 12 Jan 2026, 20:28
- Role
- Director
- Next action
- Open filing details
3
AKTS
Aktis Oncology, Inc.
- Report period
- 08 Jan 2026
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 08 Jan 2026, 20:49
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ADAP
Adaptimmune Therapeutics PLC
- Report period
- 28 Jul 2025
- Transactions
- 3
- Transaction value
- -$6,890,236
- Accepted by SEC
- 30 Jul 2025, 18:20
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ZYME
Zymeworks Inc.
- Report period
- 26 Jun 2025
- Transactions
- 3
- Transaction value
- -$12.46
- Accepted by SEC
- 27 Jun 2025, 17:50
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ZYME
Zymeworks Inc.
- Report period
- 15 May 2025
- Transactions
- 2
- Transaction value
- +$635,586
- Accepted by SEC
- 19 May 2025, 18:35
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ITOS
iTeos Therapeutics, Inc.
- Report period
- 14 May 2025
- Transactions
- 2
- Transaction value
- +$38,685,562
- Accepted by SEC
- 16 May 2025, 18:52
- Role
- 10%+ Owner
- Next action
- Open filing details
3
ITOS
iTeos Therapeutics, Inc.
- Report period
- 13 May 2025
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 13 May 2025, 19:09
- Role
- 10%+ Owner
- Next action
- Open filing details
4
PRTA
PROTHENA CORP PUBLIC LTD CO
- Report period
- 02 May 2025
- Transactions
- 3
- Transaction value
- -$50,839,807
- Accepted by SEC
- 06 May 2025, 19:06
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ZYME
Zymeworks Inc.
- Report period
- 16 Apr 2025
- Transactions
- 2
- Transaction value
- +$1,456,408
- Accepted by SEC
- 18 Apr 2025, 15:17
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ZYME
Zymeworks Inc.
- Report period
- 03 Apr 2025
- Transactions
- 2
- Transaction value
- +$3,623,970
- Accepted by SEC
- 07 Apr 2025, 18:34
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ZYME
Zymeworks Inc.
- Report period
- 31 Mar 2025
- Transactions
- 3
- Transaction value
- +$1,497,322
- Accepted by SEC
- 02 Apr 2025, 19:02
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ZYME
Zymeworks Inc.
- Report period
- 25 Mar 2025
- Transactions
- 2
- Transaction value
- +$1,227,309
- Accepted by SEC
- 27 Mar 2025, 18:53
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ZYME
Zymeworks Inc.
- Report period
- 20 Mar 2025
- Transactions
- 3
- Transaction value
- +$1,643,248
- Accepted by SEC
- 24 Mar 2025, 17:45
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ZYME
Zymeworks Inc.
- Report period
- 17 Mar 2025
- Transactions
- 3
- Transaction value
- +$2,866,553
- Accepted by SEC
- 19 Mar 2025, 18:32
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ZYME
Zymeworks Inc.
- Report period
- 11 Mar 2025
- Transactions
- 3
- Transaction value
- +$13,120,914
- Accepted by SEC
- 13 Mar 2025, 19:35
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ZYME
Zymeworks Inc.
- Report period
- 16 Jan 2025
- Transactions
- 2
- Transaction value
- +$1,963,538
- Accepted by SEC
- 21 Jan 2025, 17:34
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ZYME
Zymeworks Inc.
- Report period
- 13 Jan 2025
- Transactions
- 3
- Transaction value
- +$2,278,811
- Accepted by SEC
- 15 Jan 2025, 18:12
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ZYME
Zymeworks Inc.
- Report period
- 08 Jan 2025
- Transactions
- 2
- Transaction value
- +$2,974,819
- Accepted by SEC
- 10 Jan 2025, 18:27
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ANAB
ANAPTYSBIO, INC
- Report period
- 30 Dec 2024
- Transactions
- 3
- Transaction value
- +$1,099,642
- Accepted by SEC
- 02 Jan 2025, 18:17
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ZYME
Zymeworks Inc.
- Report period
- 30 Dec 2024
- Transactions
- 3
- Transaction value
- +$5,321,176
- Accepted by SEC
- 02 Jan 2025, 17:51
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ZYME
Zymeworks Inc.
- Report period
- 24 Dec 2024
- Transactions
- 3
- Transaction value
- +$1,882,115
- Accepted by SEC
- 27 Dec 2024, 18:41
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4/A
ZYME
Zymeworks Inc.
- Report period
- 19 Dec 2024
- Transactions
- 3
- Transaction value
- +$17,544,284
- Accepted by SEC
- 26 Dec 2024, 12:46
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
MRSN
Mersana Therapeutics, Inc.
- Report period
- 19 Dec 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 23 Dec 2024, 19:42
- Role
- 10%+ Owner
- Next action
- Open filing details
4
TNGX
Tango Therapeutics, Inc.
- Report period
- 06 Nov 2024
- Transactions
- 3
- Transaction value
- -$8,435,743
- Accepted by SEC
- 08 Nov 2024, 19:24
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ANAB
ANAPTYSBIO, INC
- Report period
- 14 Aug 2024
- Transactions
- 1
- Transaction value
- +$9,999,978
- Accepted by SEC
- 16 Aug 2024, 12:04
- Role
- 10%+ Owner
- Next action
- Open filing details
3
ADAP
Adaptimmune Therapeutics PLC
- Report period
- 08 Mar 2024
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 26 Mar 2024, 12:00
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ZYME
Zymeworks Inc.
- Report period
- 26 Dec 2023
- Transactions
- 1
- Transaction value
- +$49,999,993
- Accepted by SEC
- 23 Dec 2024, 19:53
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ZYME
Zymeworks Inc.
- Report period
- 26 Dec 2023
- Transactions
- 1
- Transaction value
- +$49,999,993
- Accepted by SEC
- 28 Dec 2023, 12:11
- Role
- 10%+ Owner
- Next action
- Open filing details
3
Mirati Therapeutics, Inc.
- Report period
- 18 Dec 2023
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 27 Dec 2023, 16:04
- Role
- 10%+ Owner
- Next action
- Open filing details
3
TNGX
Tango Therapeutics, Inc.
- Report period
- 13 Oct 2023
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 16 Oct 2023, 15:42
- Role
- 10%+ Owner
- Next action
- Open filing details
3
MRSN
Mersana Therapeutics, Inc.
- Report period
- 27 Jul 2023
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 31 Jul 2023, 13:55
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ZYME
Zymeworks Inc.
- Report period
- 16 Jun 2023
- Transactions
- 1
- Transaction value
- +$27,202,000
- Accepted by SEC
- 21 Jun 2023, 16:04
- Role
- 10%+ Owner
- Next action
- Open filing details
3
TCRX
TScan Therapeutics, Inc.
- Report period
- 26 May 2023
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 05 Jun 2023, 16:09
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ZYME
Zymeworks Inc.
- Report period
- 28 Mar 2023
- Transactions
- 1
- Transaction value
- +$1,600,000
- Accepted by SEC
- 30 Mar 2023, 17:47
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ZYME
Zymeworks Inc.
- Report period
- 19 Jan 2023
- Transactions
- 2
- Transaction value
- +$2,982,733
- Accepted by SEC
- 23 Jan 2023, 17:00
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ZYME
Zymeworks Inc.
- Report period
- 13 Jan 2023
- Transactions
- 3
- Transaction value
- +$9,697,526
- Accepted by SEC
- 18 Jan 2023, 17:27
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ZYME
Zymeworks Inc.
- Report period
- 10 Jan 2023
- Transactions
- 2
- Transaction value
- +$7,874,083
- Accepted by SEC
- 12 Jan 2023, 15:47
- Role
- 10%+ Owner
- Next action
- Open filing details
4
VYGR
Voyager Therapeutics, Inc.
- Report period
- 09 Jan 2023
- Transactions
- 3
- Transaction value
- -$7,142,343
- Accepted by SEC
- 11 Jan 2023, 17:26
- Role
- 10%+ Owner
- Next action
- Open filing details
3
LENZ
Graphite Bio, Inc.
- Report period
- 06 Jan 2023
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 06 Jan 2023, 20:30
- Role
- 10%+ Owner
- Next action
- Open filing details
3
ZYME
Zymeworks Inc.
- Report period
- 31 Oct 2022
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 01 Nov 2022, 15:23
- Role
- 10%+ Owner
- Next action
- Open filing details
4
VYGR
Voyager Therapeutics, Inc.
- Report period
- 21 Jun 2022
- Transactions
- 2
- Transaction value
- +$2,662,047
- Accepted by SEC
- 23 Jun 2022, 17:21
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ANAB
ANAPTYSBIO, INC
- Report period
- 05 May 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 09 May 2022, 06:04
- Role
- 10%+ Owner
- Next action
- Open filing details
4
PRTA
PROTHENA CORP PUBLIC LTD CO
- Report period
- 05 May 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 09 May 2022, 06:01
- Role
- 10%+ Owner
- Next action
- Open filing details
3
VYGR
Voyager Therapeutics, Inc.
- Report period
- 21 Apr 2022
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 25 Apr 2022, 21:30
- Role
- 10%+ Owner
- Next action
- Open filing details
4
PRTA
PROTHENA CORP PUBLIC LTD CO
- Report period
- 12 Jan 2022
- Transactions
- 1
- Transaction value
- +$11,250,300
- Accepted by SEC
- 12 Jan 2022, 17:12
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Odonate Therapeutics, Inc.
- Report period
- 01 Dec 2021
- Transactions
- 5
- Transaction value
- -$9,432,401
- Accepted by SEC
- 10 Dec 2021, 17:50
- Role
- 10%+ Owner
- Next action
- Open filing details
3
Odonate Therapeutics, Inc.
- Report period
- 17 Nov 2021
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 18 Nov 2021, 12:00
- Role
- 10%+ Owner
- Next action
- Open filing details
4
CRVS
Corvus Pharmaceuticals, Inc.
- Report period
- 30 Sep 2021
- Transactions
- 2
- Transaction value
- -$25,059,900
- Accepted by SEC
- 01 Oct 2021, 19:39
- Role
- 10%+ Owner
- Next action
- Open filing details
3
CRVS
Corvus Pharmaceuticals, Inc.
- Report period
- 22 Sep 2021
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 22 Sep 2021, 15:30
- Role
- 10%+ Owner
- Next action
- Open filing details
4
PRTA
PROTHENA CORP PUBLIC LTD CO
- Report period
- 18 Jun 2021
- Transactions
- 2
- Transaction value
- +$7,500,000
- Accepted by SEC
- 22 Jun 2021, 17:05
- Role
- 10%+ Owner
- Next action
- Open filing details